Evidence map›Paper›PMID 33169205›Full record

ArticleDiabetologia2021

HDL particle size is increased and HDL-cholesterol efflux is enhanced in type 1 diabetes: a cross-sectional study.

Mohamad O Ahmed, Rachel E Byrne, Agnieszka Pazderska, Ricardo Segurado, Weili Guo, Anjuli Gunness, Isolda Frizelle, Mark Sherlock, Khalid S Ahmed, Anne McGowan and 4 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Review
  3. HDL metabolism and function in diabetes mellitus.Nature reviews. Endocrinology · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. HDL Function across the Lifespan: From Childhood, to Pregnancy, to Old Age.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Mohamad O AhmedRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
Rachel E ByrneDiabetes Complications Research Centre, School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
Agnieszka PazderskaRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
Ricardo SeguradoSchool of Public Health, Physiotherapy, and Sports Science, University College Dublin, Belfield, Dublin, Ireland.
Weili GuoDiabetes Complications Research Centre, School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
Anjuli GunnessRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
Isolda FrizelleRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
Mark SherlockRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
Khalid S AhmedRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
Anne McGowanRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
Kevin MooreRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
Gerard BoranDepartment of Chemical Pathology, Tallaght University Hospital, Dublin, Ireland.
Fiona C McGillicuddyDiabetes Complications Research Centre, School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
James GibneyRobert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland. James.Gibney@TUH.ie.
Tallaght University Hospital · IEUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisThe prevalence of atherosclerosis is increased in type 1 diabetes despite normal-to-high HDL-cholesterol levels. The cholesterol efflux capacity (CEC) of HDL is a better predictor of cardiovascular events than static HDL-cholesterol. This cross-sectional study addressed the hypothesis that impaired HDL function contributes to enhanced CVD risk within type 1 diabetes.

methodsWe compared HDL particle size and concentration (by NMR), total CEC, ATP-binding cassette subfamily A, member 1 (ABCA1)-dependent CEC and ABCA1-independent CEC (by determining [

resultsCompared with non-diabetic participants, total HDL particle concentration was lower (mean ± SD 31.01 ± 8.66 vs 34.33 ± 8.04 μmol/l [mean difference (MD) -3.32 μmol/l]) in participants with type 1 diabetes. However, large HDL particle concentration was greater (9.36 ± 3.98 vs 6.99 ± 4.05 μmol/l [MD +2.37 μmol/l]), resulting in increased mean HDL particle size (9.82 ± 0.57 vs 9.44 ± 0.56 nm [MD +0.38 nm]) (p < 0.05 for all). Total CEC (14.57 ± 2.47%CEC/4 h vs 12.26 ± 3.81%CEC/4 h [MD +2.31%CEC/4 h]) was greater in participants with type 1 diabetes relative to non-diabetic participants. Increased HDL particle size was independently associated with increased total CEC; however, following adjustment for this in multivariable analysis, CEC remained greater in participants with type 1 diabetes. Both components of CEC, ABCA1-dependent (6.10 ± 2.41%CEC/4 h vs 5.22 ± 2.57%CEC/4 h [MD +0.88%CEC/4 h]) and ABCA1-independent (8.47 ± 1.79% CEC/4 h vs 7.05 ± 1.76% CEC/4 h [MD +1.42% CEC/4 h]) CEC, were greater in type 1 diabetes but the increase in ABCA1-dependent CEC was less marked and not statistically significant in multivariable analysis. CIMT was increased in participants with type 1 diabetes but in multivariable analysis it was only associated negatively with age and BMI. CONCLUSIONS/

interpretationHDL particle size but not HDL-cholesterol level is independently associated with enhanced total CEC. HDL particle size is greater in individuals with type 1 diabetes but even after adjusting for this, total and ABCA1-independent CEC are enhanced in type 1 diabetes. Further studies are needed to understand the mechanisms underlying these effects, and whether they help attenuate progression of atherosclerosis in this high-risk group. Graphical abstract.

Indexed as

AdultAnimalsAtherosclerosisATP Binding Cassette Transporter 1BiomarkersCase-Control StudiesCell LineCholesterol, HDLCross-Sectional StudiesDiabetes Mellitus, Type 1FemaleHumansMacrophagesMaleMiceMice, Inbred BALB CABCA1 protein, humanAbca1 protein, mouseATP Binding Cassette Transporter 1BiomarkersCholesterol, HDLHDL-cholesterol efflux capacityHDL particle sizeType 1 diabetes

Identifiers

PMID33169205
OpenAlexW3102812123

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.